| Risk factors and outcome of COVID-19 in patients with hematological malignancies JL Piñana, R Martino, I García-García, R Parody, MD Morales, G Benzo, ... Experimental Hematology & Oncology 9, 1-16, 2020 | 137 | 2020 |
| Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma G Iacoboni, G Villacampa, N Martinez‐Cibrian, R Bailén, L Lopez Corral, ... Cancer Medicine 10 (10), 3214-3223, 2021 | 86 | 2021 |
| Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma M Kwon, G Iacoboni, JL Reguera, LL Corral, RH Morales, ... Haematologica 108 (1), 110, 2023 | 58 | 2023 |
| Uric acid excretion in healthy subjects: a nomogram to assess the mechanisms underlying purine metabolic disorders. BJR Puig JG, Torres RJ, de Miguel E, Sánchez A, Bailén R Metabolism. 61 ((4)), 512-8, 2012 | 58 | 2012 |
| Tubular urate transporter gene polymorphisms differentiate patients with gout who have normal and decreased urinary uric acid excretion. PJG Torres RJ, de Miguel E, Bailén R, Banegas JR J Rheumatol. 41 ((9)), 1863-70, 2014 | 46 | 2014 |
| Infectious Complications Subcommittee of the Spanish Hematopoietic Stem Cell Transplantation and Cell Therapy Group (GETH). Risk factors and outcome of COVID-19 in patients … JL Piñana, R Martino, I García-García, R Parody, MD Morales, G Benzo, ... Exp Hematol Oncol 9 (1), 21, 2020 | 34 | 2020 |
| Posttransplant cyclophosphamide vs cyclosporin A and methotrexate as GVHD prophylaxis in matched sibling transplantation M Kwon, R Bailén, MJ Pascual-Cascón, AI Gallardo-Morillo, ... Blood advances 3 (21), 3351-3359, 2019 | 31 | 2019 |
| Metabolic syndrome in primary gout. PJG González-Senac NM, Bailén R, Torres RJ, de Miguel E Nucleosides Nucleotides Nucleic Acids. 33 ((4-6)), 185-91, 2014 | 31 | 2014 |
| Post-transplant cyclophosphamide for GVHD prophylaxis compared to ATG-based prophylaxis in unrelated donor transplantation R Bailén, M Kwon, MJ Pascual-Cascón, C Ferrà, J Sanz, ... Annals of Hematology 100, 541-553, 2021 | 27 | 2021 |
| Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO/GETH Spanish groups M Bastos-Oreiro, A Gutierrez, JL Reguera, G Iacoboni, L López-Corral, ... Frontiers in immunology 13, 855730, 2022 | 24 | 2022 |
| Short tandem repeats (STRs) as biomarkers for the quantitative follow-up of chimerism after stem cell transplantation: methodological considerations and clinical application A Navarro-Bailón, D Carbonell, A Escudero, M Chicano, P Muñiz, ... Genes 11 (9), 993, 2020 | 24 | 2020 |
| Hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS) following treatment with tisagenlecleucel RM Martín‐Rojas, I Gómez‐Centurión, R Bailén, M Bastos, ... Clinical Case Reports 10 (1), e05209, 2022 | 21 | 2022 |
| Factors predicting peripheral blood progenitor cell mobilization in healthy donors in the era of related alternative donors: experience from a single center R Bailén, AM Pérez‐Corral, C Pascual, M Kwon, D Serrano, J Gayoso, ... Journal of Clinical Apheresis 34 (4), 373-380, 2019 | 16 | 2019 |
| Cytokine release syndrome after allogeneic stem cell transplantation with posttransplant cyclophosphamide L Solán, E Landete, R Bailén, N Dorado, G Oarbeascoa, J Anguita, ... Hematological Oncology 38 (4), 597-603, 2020 | 14 | 2020 |
| Allogeneic stem-cell transplantation in HIV-1-infected patients with high-risk hematological disorders M Kwon, R Bailén, P Balsalobre, M Jurado, A Bermudez, J Badiola, ... Aids 33 (9), 1441-1447, 2019 | 14 | 2019 |
| Safety and efficacy of two anakinra dose regimens for refractory CRS or ICANS after CAR T-cell therapy N Gazeau, P Barba, G Iacoboni, M Kwon, R Bailen, JL Reguera, LL Corral, ... Blood 138, 2816, 2021 | 13 | 2021 |
| Evolution of the role of haploidentical stem cell transplantation: past, present, and future M Kwon, R Bailén, JL Díez-Martín Expert Review of Hematology 13 (8), 835-850, 2020 | 13 | 2020 |
| Recent bendamustine treatment before apheresis has a negative impact on outcomes in patients with large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy G Iacoboni, V Navarro, AÁ Martín-López, K Rejeski, M Kwon, KA Jalowiec, ... Journal of Clinical Oncology 42 (2), 205-217, 2024 | 11 | 2024 |
| Post-transplantation cyclophosphamide after HLA identical compared to haploidentical donor transplant in acute myeloid leukemia: a study on behalf of GETH-TC R Bailén, MJ Pascual-Cascón, M Guerreiro, L López-Corral, A Chinea, ... Transplantation and Cellular Therapy 28 (4), 204. e1-204. e10, 2022 | 11 | 2022 |
| Management of donor-specific antibodies in haploidentical transplant: Multicenter experience from the Madrid group of hematopoietic transplant R Bailén, JL Vicario, L Solán, I Sanchez-Vadillo, P Herrera, M Calbacho, ... Frontiers in immunology 12, 674658, 2021 | 11 | 2021 |
